We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?
Read MoreHide Full Article
Supernus Pharmaceuticals (SUPN - Free Report) shares rallied 5.2% in the last trading session to close at $50.44. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5% gain over the past four weeks.
Supernus Pharmaceuticals’ share price gain can likely be attributed to the growing investor confidence in its growing neuroscience business. The company's strong commercial performance has been driven by robust growth in Qelbree for ADHD, continued momentum for Gocovri, increasing collaboration revenue from Zurzuvae, and contributions from the recently launched Onapgo, resulting in solid year-over-year revenue growth across its key products. The company expects to submit a second supplier application for Onapgo to the FDA in the third quarter of 2026. Meanwhile, progress in pipeline candidates such as SPN-817 for epilepsy and SPN-820 for treatment-resistant depression has been encouraging.
This drugmaker is expected to post quarterly earnings of $0.55 per share in its upcoming report, which represents a year-over-year change of -39.6%. Revenues are expected to be $205.04 million, up 23.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Supernus, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SUPN going forward to see if this recent jump can turn into more strength down the road.
Supernus is a member of the Zacks Medical - Generic Drugs industry. One other stock in the same industry, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) , finished the last trading session 4.1% lower at $33.24. TEVA has returned 0.6% over the past month.
Teva Pharmaceutical Industries' consensus EPS estimate for the upcoming report has changed -1.3% over the past month to $0.39. Compared to the company's year-ago EPS, this represents a change of -40.9%. Teva Pharmaceutical Industries currently boasts a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?
Supernus Pharmaceuticals (SUPN - Free Report) shares rallied 5.2% in the last trading session to close at $50.44. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 5% gain over the past four weeks.
Supernus Pharmaceuticals’ share price gain can likely be attributed to the growing investor confidence in its growing neuroscience business. The company's strong commercial performance has been driven by robust growth in Qelbree for ADHD, continued momentum for Gocovri, increasing collaboration revenue from Zurzuvae, and contributions from the recently launched Onapgo, resulting in solid year-over-year revenue growth across its key products. The company expects to submit a second supplier application for Onapgo to the FDA in the third quarter of 2026. Meanwhile, progress in pipeline candidates such as SPN-817 for epilepsy and SPN-820 for treatment-resistant depression has been encouraging.
This drugmaker is expected to post quarterly earnings of $0.55 per share in its upcoming report, which represents a year-over-year change of -39.6%. Revenues are expected to be $205.04 million, up 23.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Supernus, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on SUPN going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Supernus is a member of the Zacks Medical - Generic Drugs industry. One other stock in the same industry, Teva Pharmaceutical Industries Ltd. (TEVA - Free Report) , finished the last trading session 4.1% lower at $33.24. TEVA has returned 0.6% over the past month.
Teva Pharmaceutical Industries' consensus EPS estimate for the upcoming report has changed -1.3% over the past month to $0.39. Compared to the company's year-ago EPS, this represents a change of -40.9%. Teva Pharmaceutical Industries currently boasts a Zacks Rank of #3 (Hold).